scholarly journals Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy - a single centre, open-label study

2011 ◽  
Vol 13 (1) ◽  
pp. R7 ◽  
Author(s):  
Eliza K Pontifex ◽  
Danielle M Gerlag ◽  
Martina Gogarty ◽  
Marjolein Vinkenoog ◽  
Adrian Gibbs ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Psoriatic Arthritis ◽  
Magnetic Resonance ◽  
Biologic Therapy ◽  
Resonance Imaging ◽  
Single Centre ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Cell Expression

scholarly journals Open-label study of infliximab treatment for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammation

2002 ◽  
Vol 47 (5) ◽  
pp. 506-512 ◽  
Author(s):  
Christian Antoni ◽  
Claudia Dechant ◽  
P. D. Hanns-Martin Lorenz ◽  
Joerg Wendler ◽  
Alexandra Ogilvie ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Psoriatic Arthritis ◽  
Magnetic Resonance ◽  
Infliximab Treatment ◽  
Resonance Imaging ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Effect of adalimumab on joint disease: features of patients with psoriatic arthritis detected by magnetic resonance imaging

2009 ◽  
Vol 69 (01) ◽  
pp. 206-209 ◽  
Author(s):  
A P Anandarajah ◽  
P Ory ◽  
D Salonen ◽  
C Feng ◽  
R L Wong ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Psoriatic Arthritis ◽  
Magnetic Resonance ◽  
Joint Disease ◽  
Resonance Imaging ◽  
Open Label ◽  
Magnetic Resonance Imaging Mri ◽  
The Impact ◽  
Joint Erosion

Background:Bone marrow oedema (BMO), synovitis, effusion and joint erosion on magnetic resonance imaging (MRI) may be used as outcome measures in psoriatic arthritis (PsA).Objective:To assess the impact of adalimumab on BMO, synovitis, effusion and erosions in PsA, as measured by MRI.Methods:Fifteen patients with active PsA (⩾3 tender and ⩾3 swollen joints) were enrolled in an open-label pilot study. Each received adalimumab subcutaneously every other week for 24 weeks. MRI was obtained at baseline and 24 weeks.Results:MRI was available for 11 patients, pre and post-therapy. BMO and effusion scores improved markedly after 24 weeks of adalimumab, while no significant change was noted in erosion score. An unanticipated finding, however, was the lack of improvement in the MRI synovitis score.Conclusions:Improvement in BMO and unchanged erosion scores may explain the “anti-erosive” effects of adalimumab in PsA. Persistence of BMO and synovitis on MRI suggests ongoing disease activity and supports the continuation of long-term anti-TNF therapy.

scholarly journals Cartilage Degradation in Psoriatic Arthritis Is Associated With Increased Synovial Perfusion as Detected by Magnetic Resonance Imaging

2020 ◽  
Vol 7 ◽  
Author(s):  
Daniel B. Abrar ◽  
Christoph Schleich ◽  
Anja Müller-Lutz ◽  
Miriam Frenken ◽  
K. Ludger Radke ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Psoriatic Arthritis ◽  
Magnetic Resonance ◽  
Cartilage Degradation ◽  
Resonance Imaging

scholarly journals Magnetic Resonance Imaging in Psoriatic Arthritis — Update on Current Status and Future Perspectives: A Report from the GRAPPA 2010 Annual Meeting

2012 ◽  
Vol 39 (2) ◽  
pp. 408-412 ◽  
Author(s):  
MIKKEL ØSTERGAARD ◽  
RENÉ PANDURO POGGENBORG
Keyword(s):  
Magnetic Resonance Imaging ◽  
Psoriatic Arthritis ◽  
Magnetic Resonance ◽  
Annual Meeting ◽  
Current Status ◽  
Future Research ◽  
Future Perspectives ◽  
Resonance Imaging ◽  
Primary Driver ◽  
Magnetic Resonance Imaging Mri

The potential of magnetic resonance imaging (MRI) for use in clinical practice and research has gained increasing interest over the last decade. International collaborative initiatives from GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) and/or OMERACT (Outcome Measures in Rheumatology) may contribute to facilitating research, identifying appropriate areas for use, and reaching consensus on the optimal examination technique. Accordingly, GRAPPA, a primary driver of international research in psoriasis and psoriatic arthritis (PsA), has focused on the current use and future development of MRI and other modern imaging modalities in PsA. This review, presented at the GRAPPA 2010 annual meeting, describes the current status of MRI in PsA, with a focus on its use in diagnosis, monitoring, and prediction of the disease course and treatment response. Important areas for future research are also outlined.

Sign in / Sign up

Export Citation Format

Share Document